14170-83-3

Basic information

• Product Name: 2-Furancarboxamide, N-(4-methoxyphenyl)-5-nitro-
• CAS NO: 14170-83-3
• Molecular Formula: C12H10N2O5
• Molecular Weight: 262.222
• Mol File: 14170-83-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-Furancarboxamide, N-(4-methoxyphenyl)-5-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Furancarboxamide, N-(4-methoxyphenyl)-5-nitro-(14170-83-3)
• EPA Substance Registry System: 2-Furancarboxamide, N-(4-methoxyphenyl)-5-nitro-(14170-83-3)

Safety Data

• Hazardous Substances Data: 14170-83-3(Hazardous Substances Data)

Upstream product

• 645-12-5 5-nitro-2-furoic acid 
• 104-94-9 4-methoxy-aniline 
• 25084-14-4 5-nitrofuran-2-carboxylic chloride 

Downstream Products

• 15182-22-6 1-(4-methoxy-phenyl)-5-(5-nitro-furan-2-yl)-1H-tetrazole 

Relevant articles and documents

Diarylamide compound and application thereof

The invention discloses a use of a diarylamide compound with a structure shown as a formula (I), and a pharmaceutically acceptable salt thereof in the preparation of a medicine serving as a urea transporter inhibitor, and the novel diarylamide compound. T

Heterocyclic amides with anti-tuberculosis activity

Compounds having the general structure: wherein A is selected from the group consisting of oxygen, sulfur, and NR15, and R15 is selected from the group consisting of H, alkyl, aryl, substituted alkyl, and substituted aryl; B,D, and E are each independently selected from the group consisting of CH, nitrogen, sulfur and oxygen; R1 is selected from the group consisting of nitro, halo, alkyl ester, arylsulfanyl, arylsulfinyl, arylsulfonyl and sulfonic acid; t is an integer from 1 to 3; and X is a substituted amide, and methods of using the novel compounds for treating infections caused by microorganisms, including Mycobacterium tuberculosis.

Synthesis and evaluation of nitrofuranylamides as novel antituberculosis agents

In an effort to develop new and more potent therapies to treat tuberculosis, a library of compounds was screened for M. tuberculosis UDP-Gal mutase inhibition. Nitrofuranylamide 1 was identified as a hit in this screen, possessing good antituberculosis activity. This paper describes the synthesis and evaluation of an expanded set of nitrofuranylamides. We have discovered a number of nitrofuranylamides with submicromolar M. tuberculosis MIC values and acceptable therapeutic indexes. The MIC activity did not correlate with UDP-Gal mutase inhibition, suggesting an alternative primary cellular target was responsible for the antituberculosis activity. The compounds were only active against mycobacteria of the tuberculosis complex. On the basis of these results, four compounds were selected for in vivo testing in a mouse model of tuberculosis infection, and of these compounds one showed significant antituberculosis activity.